Robert T. OʼDonnell

Author

Robert T. OʼDonnell

Also Known As

O'Donnell, Rob, R O'Donnell, R T O'Donnell, R. O'Donnell, R. Odonnell, R. O’Donnell, R. T. O'Donnell, R.T. O'Donnell, RL O'Donnell, ROBERT T. O'DONNELL

151

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

University of California, Davis University of California Davis Medical Center Palmetto Hematology Oncology VA Northern California Health Care System University of California, San Francisco

About

Robert T. OʼDonnell is an author at University of California, Davis specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	19	490
2	Health Sciences	4	4	95
3	Allergy	2	2	25
4	Engineering	1	1	14
5	Allergy Medicine	1	1	10

Robert T. OʼDonnell

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment Primo N. Lara, Roger Higdon, Nelson Lim, Journal of Clinical Oncology	2001	601
Epidemiology of venous thromboembolism in 9489 patients with malignant glioma Thomas J. Semrad, Robert T. OʼDonnell, Ted Wun, Journal of neurosurgery	2007	282
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts Sally J. DeNardo, David L. Kukis, Linda A. Kroger, Proceedings of the National Academy of Sciences	1997	109
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody Carol M. Richman, Sally J. DeNardo, Robert T. OʼDonnell, Clinical Cancer Research	2005	84
Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. Sally J. DeNardo, Elissa L. Kramer, Robert T. OʼDonnell, PubMed	1997	84
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. Robert T. OʼDonnell, Gerald L. DeNardo, David L. Kukis, PubMed	1999	81
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐<scp>H</scp>odgkin lymphoma Joseph M. Tuscano, Mrinal P. Dutia, Karen Giselle Chee, British Journal of Haematology	2014	75
Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. Sui Shen, Gerald L. DeNardo, George Sgouros, PubMed	1999	68
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and <sup>90</sup>yttrium‐DOTA‐peptide‐ChL6 Robert T. OʼDonnell, Sally J. DeNardo, Laird Miers, The Prostate	2001	68
Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients Gary R. Mirick, Robert T. OʼDonnell, Sally J. DeNardo, Nuclear Medicine and Biology 67Cu-antibody ConjugateMedicineImmunologyPathologyOncology	1999	68

Page 1